| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3978944 | Bulletin du Cancer | 2012 | 9 Pages |
Abstract
Antiangiogenic agents appear as major therapeutic options in renal, colorectal and breast cancer. Their part in thoracic oncology is still limited today except for bevacizumab. We review the current limits of antiangiogenic agents in terms of efficacy, activity, tolerance and therapeutic strategies. Problems about predictive biomarkers and cost-effectiveness of antiangiogenic agents in thoracic oncology are also mentioned.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Ãric Dansin, Géraldine Lauridant, Bachar Chahine,